A Phase 3 interventional study of Flublok and Afluria in Influenza, sponsored by Protein Sciences Corporation. Completed at 14 sites in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-02-18.
Sponsored by Protein Sciences Corporation · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing FluBlok in Influenza, Human — none open to participants now, none under way, none of them phase 3. FluBlok · Influenza, Human.
Among the 11 studies testing FluBlok in Influenza, Human, this one is the 2nd largest by enrollment, is the only one that started in 2013, is one of 3 in phase 3, and was the 6th registered.
2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.
Browse Influenza, Human studies →None of the 11 studies testing FluBlok in Influenza, Human is open now. The open studies under Influenza, Human, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 4 · Phase 4 5
First in 2004; this study’s year is marked. 1 started in 2013.
This study's enrollment of 2,640 is above the median of 227 across 1,957 interventional studies indexed under Influenza, Human.
Median enrollment 606 across the 11 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 11 have an industry lead sponsor. The 8 most frequent:
Protein Sciences Corporation is the lead sponsor of 12 studies on the registry; none are open to participants now.
12 studies in Influenza, Human by Protein Sciences Corporation: none open now, none under way, none of them phase 3. Of 12 finished, 8 (67%) have results posted.
Among the 12 studies in Influenza, Human by Protein Sciences Corporation, this one is the 2nd largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2013, is one of 6 in phase 3, and was the 7th registered.
Protein Sciences Corporation’s Influenza, Human studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing FluBlok in Influenza, Human, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Protein Sciences Corporation’s 12 in Influenza, Human:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The hypothesis for this trial is that the incidence of a pre-defined composite of common systemic hypersensitivity adverse events for Flublok recipients is non-inferior to that reported for licensed IIV recipients. Another hypothesis is that the safety and reactogenicity of Flublok is clinically acceptable, i.e. consistent with the overall safety profiles previously observed with Flublok and with the licensed comparator.
The Advisory Committee on Immunization Practices (ACIP) recommends that all people aged 6 months and older be immunized to prevent influenza. Currently the only approved influenza vaccine across the entire age group is inactivated influenza vaccine (IIV). A Biologics Licensing Application (BLA) for Flublok was approved by the FDA for influenza immunization of adults 18-49 years of age. Additional safety and, ultimately efficacy, data is needed to support use in adults ≥50 years of age, an important age group as adults ≥65 years of age are among those at increased risk of influenza complications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Flublok containing 3x45µg (135µg total) of recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and influenza B viruses in a total volume of 0.5 mL
Biological: Flublok
Afluria, containing 3x15µg (45µg total), of trivalent, inactivated influenza vaccine (licensed IIV) containing influenza antigen derived from A/H1N1 and A/H3N2 and influenza B viruses in a total volume of 0.5 mL
Biological: Afluria
A Biologics Licensing Application (BLA) for Flublok was approved by the FDA for influenza immunization of adults 18-49 years of age. Flublok is produced using recombinant technology under serum-free conditions.
Afluria is approved for use in persons 5 years of age and older and is produced by inactivation and disruption of live influenza virus grown in embryonated chicken eggs.
Number of Participants With Common Hypersensitivity Reactions as Measure of Safety
Number of participants who experience a pre-defined common systemic hypersensitivity adverse event, including rash, urticaria, swelling or edema through Day 30 post-vaccine administration.
Time frame: 30 Days
Subjects With at Least One Unsolicited Adverse Event in the 30 Days Following Vaccine Administration
Subjects with at least one serious adverse event and subjects with at least one medically-attended unsolicited adverse event occurring during the 30 days following vaccine administration
Time frame: 30 Days
Number of Participants With Local and Systemic Events Reported as a Measure of Safety
Number of solicited local and systemic events of reactogenicity reported with the help of a memory aid during the seven days following vaccine administration.
Time frame: 7 Days
Subjects With at Least One Hypersensitivity Event Reported on Day 0 and Days 0-7 Following Vaccine Administration as a Measure of Safety
Subjects with at least one pre-defined common systemic hypersensitivity adverse event, including rash, urticaria, swelling or non-dependent edema on Day 0 and for Days 0 to 7 following vaccine administration
Time frame: 7 Days
Subjects were recruited at outpatient medical clinics over a period of five weeks.
| Milestone | Flublok | Afluria |
|---|---|---|
| Started | 1319 | 1321 |
| Completed | 1314 | 1314 |
| Not completed | 5 | 7 |
| Withdrew: Lost to follow-up | 5 | 6 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Number of participants who experience a pre-defined common systemic hypersensitivity adverse event, including rash, urticaria, swelling or edema through Day 30 post-vaccine administration.
| participants | Flublok | Afluria |
|---|---|---|
| Number of Participants With Common Hypersensitivity Reactions as Measure of Safety | 31 | 21 |
Subjects with at least one serious adverse event and subjects with at least one medically-attended unsolicited adverse event occurring during the 30 days following vaccine administration
| participants | Flublok | Afluria |
|---|---|---|
| Serious Adverse Events (SAEs) | 5 | 10 |
| Medically-Attended Unsolicited Adverse Events | 53 | 51 |
Number of solicited local and systemic events of reactogenicity reported with the help of a memory aid during the seven days following vaccine administration.
| participants | Flublok | Afluria |
|---|---|---|
| Number of Participants With Local and Systemic Events Reported as a Measure of Safety | 432 | 480 |
Subjects with at least one pre-defined common systemic hypersensitivity adverse event, including rash, urticaria, swelling or non-dependent edema on Day 0 and for Days 0 to 7 following vaccine administration
| participants | Flublok | Afluria |
|---|---|---|
| Day 0 | 5 | 3 |
| Days 0-7 | 25 | 12 |
Collected over 30 days following vaccine administration. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Flublok | — | 5/1,314 (0.4%) | 20/1,314 (1.5%) |
| Afluria | — | 10/1,313 (0.8%) | 16/1,313 (1.2%) |
| Event | Flublok | Afluria |
|---|---|---|
| SepsisInfections and infestations | 0/1314 | 2/1313 |
| Myocardial InfarctionCardiac disorders | 1/1314 | 2/1313 |
| Cerebellar Stroke SyndromeNervous system disorders | 0/1314 | 1/1313 |
| Diabetic KetoacidosisEndocrine disorders | 0/1314 | 1/1313 |
| Alcoholic HepatitisInjury, poisoning and procedural complications | 1/1314 | 1/1313 |
| Leg FractureInjury, poisoning and procedural complications | 0/1314 | 1/1313 |
| PneumoniaInfections and infestations | 0/1314 | 1/1313 |
| HypertensionCardiac disorders | 0/1314 | 1/1313 |
| AppendicitisInfections and infestations | 0/1314 | 1/1313 |
| Prostate CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/1314 | 0/1313 |
| Event | Flublok | Afluria |
|---|---|---|
| HeadacheNervous system disorders | 8/1314 | 12/1313 |
| DiarrheaGastrointestinal disorders | 12/1314 | 4/1313 |
The primary analysis population includes all randomized subjects who received a dose of study vaccine and for whom some safety data were available after administration of vaccine. Subjects were analyzed according to the vaccine received, regardless of whether this was the treatment group to which they were randomized.
| Age, Continuous(years) | Flublok | Afluria | Total |
|---|---|---|---|
| Mean | 64 (50 to 99) | 64 (50 to 93) | 64 (50 to 99) |
| Age, Categorical(Participants) | Flublok | Afluria | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 672 | 665 | 1337 |
| >=65 years | 642 | 648 | 1290 |
| Sex: Female, Male(Participants) | Flublok | Afluria | Total |
|---|---|---|---|
| Female | 730 | 725 | 1455 |
| Male | 584 | 588 | 1172 |
| Race (NIH/OMB)(Participants) | Flublok | Afluria | Total |
|---|---|---|---|
| American Indian or Alaska Native | 8 | 6 | 14 |
| Asian | 7 | 5 | 12 |
| Native Hawaiian or Other Pacific Islander | 1 | 2 | 3 |
| Black or African American | 197 | 212 | 409 |
| White | 1098 | 1083 | 2181 |
| More than one race | 3 | 5 | 8 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Flublok | Afluria | Total |
|---|---|---|---|
| Hispanic or Latino | 105 | 99 | 204 |
| Not Hispanic or Latino | 1209 | 1214 | 2423 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Flublok | Afluria | Total |
|---|---|---|---|
| United States | 1314 | 1313 | 2627 |
The record gives a start of Mar 2013, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2015, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: FluBlok
Protein Sciences Corporation